Summary

BAVENCIO® (avelumab)—a STANDARD OF CARE in first-line maintenance treatment of locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy1,2

Avelumab is the ONLY
maintenance IO with
NCCN Category 1 and
Preferred status3
Superior OS vs BSC alone
demonstrated in the largest
Phase 3 pivotal trial
(N=700), with follow-up
data of 38 months4,8-11
Established safety
profile; no new safety
signals observed in the
follow-up period4,8
A treatment option
regardless of
cisplatin eligibility3
BAVENCIO warnings and precautions
  • Severe and fatal immune-mediated adverse reactions
    1. Immune-mediated pneumonitis
    2. Immune-mediated colitis
    3. Hepatotoxicity and immune-mediated hepatitis
    4. Immune-mediated endocrinopathies
    5. Immune-mediated nephritis with renal dysfunction
    6. Immune-mediated dermatologic adverse reactions
    7. Other immune-mediated adverse reactions
  • Infusion-related reactions
  • Complications of allogeneic hematopoietic stem cell transplantation
  • Embryo-fetal toxicity

See Safety Profile for more information on BAVENCIO warnings and precautions.

Most common adverse reactions

The most common adverse reactions (≥20%) in patients receiving BAVENCIO + BSC vs BSC alone were:

  • Fatigue (35% vs 13%)
  • Musculoskeletal pain (24% vs 15%)
  • Urinary tract infection (20% vs 11%)
  • Rash (20% vs 2.3%)
Category 1=Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
BSC=best supportive care; Preferred intervention=Interventions that are based on superior efficacy, safety, and evidence; and,
when appropriate, affordability.
NCCN=National Comprehensive Cancer Network® (NCCN®)